slotkoers
Korea S.E.
00:00:00 30-04-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
6.970
KRW
|
-1,13%
|
|
+1,31%
|
-20,62%
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
645.305
|
464.141
|
915.063
|
709.999
|
269.879
|
291.422
|
Bedrijfswaarde
1 |
621.283
|
409.640
|
859.183
|
617.120
|
193.300
|
234.641
|
K/w-verhouding
|
37,7
x
|
-90,9
x
|
75,6
x
|
73,1
x
|
-23.726
x
|
-30,1
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
1,14%
|
Marktkapitalisatie/omzet
|
31,3
x
|
55,6
x
|
20,1
x
|
24,2
x
|
19,3
x
|
30,4
x
|
Bedrijfswaarde/omzet
|
30,2
x
|
49,1
x
|
18,9
x
|
21,1
x
|
13,8
x
|
24,5
x
|
Bedrijfswaarde/EBITDA
|
102
x
|
-139
x
|
49,6
x
|
53,1
x
|
2.204
x
|
-171
x
|
Bedrijfswaarde/FCF
|
163
x
|
-143
x
|
-183
x
|
18,8
x
|
-533
x
|
-27,4
x
|
FCF Yield
|
0,61%
|
-0,7%
|
-0,55%
|
5,31%
|
-0,19%
|
-3,65%
|
Price to Book
|
8,3
x
|
7,25
x
|
10,7
x
|
7,01
x
|
2,54
x
|
3,01
x
|
Aantal aandelen (in duizenden)
|
29.945
|
29.945
|
32.857
|
33.729
|
33.195
|
33.192
|
Referentieprijs
2 |
21.550
|
15.500
|
27.850
|
21.050
|
8.130
|
8.780
|
Datum van publicatie
|
19-03-19
|
18-03-20
|
17-03-21
|
16-03-22
|
20-03-23
|
13-03-24
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
20.584
|
8.347
|
45.433
|
29.308
|
14.007
|
9.585
|
EBITDA
1 |
6.106
|
-2.945
|
17.305
|
11.614
|
87,7
|
-1.373
|
Bedrijfsresultaat (EBIT)
1 |
5.166
|
-4.368
|
15.736
|
10.077
|
-1.479
|
-3.285
|
Operationele Marge
|
25,1%
|
-52,33%
|
34,64%
|
34,38%
|
-10,56%
|
-34,27%
|
Resultaat voor belastingen (EBT)
1 |
7.312
|
-1.915
|
17.051
|
10.575
|
8.319
|
-10.837
|
Nettowinst (verlies)
1 |
8.711
|
-3.187
|
14.948
|
9.728
|
5.712
|
-9.695
|
Nettomarge
|
42,32%
|
-38,18%
|
32,9%
|
33,19%
|
40,78%
|
-101,15%
|
WPA
2 |
571,0
|
-170,5
|
368,2
|
288,0
|
-0,3427
|
-292,1
|
Free Cash Flow
1 |
3.810
|
-2.857
|
-4.705
|
32.785
|
-362,7
|
-8.555
|
FCF-marge
|
18,51%
|
-34,23%
|
-10,36%
|
111,86%
|
-2,59%
|
-89,25%
|
Kasstroomconversie (ebitda)
|
62,39%
|
-
|
-
|
282,29%
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
43,73%
|
-
|
-
|
337,02%
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
100,0
|
Datum van publicatie
|
19-03-19
|
18-03-20
|
17-03-21
|
16-03-22
|
20-03-23
|
13-03-24
|
Fiscaal tijdperk: december |
2022 Q2
|
2022 Q3
|
2023 Q3
|
---|
Omzet
1 |
2,733
|
2,829
|
1,671
|
EBITDA
|
-
|
-
|
-
|
Bedrijfsresultaat (EBIT)
|
-1,518
|
-0,4623
|
-
|
Operationele Marge
|
-55,55%
|
-16,34%
|
-
|
Resultaat voor belastingen (EBT)
|
-
|
-
|
-
|
Nettowinst (verlies)
|
-
|
-
|
-
|
Nettomarge
|
-
|
-
|
-
|
WPA
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
Datum van publicatie
|
16-08-22
|
14-11-22
|
14-11-23
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
24.023
|
54.501
|
55.881
|
92.880
|
76.580
|
56.781
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
3.810
|
-2.857
|
-4.705
|
32.785
|
-363
|
-8.555
|
ROE (netto-inkomsten/eigen vermogen)
|
25,1%
|
-6,12%
|
19,9%
|
10,4%
|
5,5%
|
-9,56%
|
ROA (netto-inkomsten/totale activa)
|
6,43%
|
-3,8%
|
10,4%
|
4,96%
|
-0,63%
|
-1,71%
|
Totale activa
1 |
135.475
|
83.956
|
144.059
|
196.078
|
-909.395
|
565.693
|
Nettoactief per aandeel
2 |
2.597
|
2.137
|
2.595
|
3.005
|
3.199
|
2.914
|
Cashflow per aandeel
2 |
1.411
|
1.781
|
1.824
|
2.229
|
778,0
|
1.235
|
Capex
1 |
551
|
300
|
4.852
|
3.046
|
2.229
|
7.791
|
Capex/omzet
|
2,67%
|
3,6%
|
10,68%
|
10,39%
|
15,91%
|
81,28%
|
Datum van publicatie
|
19-03-19
|
18-03-20
|
17-03-21
|
16-03-22
|
20-03-23
|
13-03-24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -20,62% | 167 mln. | | -3,05% | 102 mld. | | +1,51% | 96,09 mld. | | +2,13% | 22,28 mld. | | -16,86% | 21,4 mld. | | -9,05% | 18,14 mld. | | -39,98% | 17,02 mld. | | -14,17% | 16,09 mld. | | +6,56% | 13,83 mld. | | +33,32% | 11,97 mld. |
Biotherapeutische geneesmiddelen
|